<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="132863">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01978678</url>
  </required_header>
  <id_info>
    <org_study_id>Aperitif</org_study_id>
    <nct_id>NCT01978678</nct_id>
  </id_info>
  <brief_title>Does Asthma Phenotype Have Impact on Disease Control</brief_title>
  <acronym>Aperitif</acronym>
  <official_title>Does Asthma Phenotype Have Impact on Disease Control - Can Detection of Inflammation and Hyper Responsiveness Ensure Stable Disease Faster</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bispebjerg Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bispebjerg Hospital</source>
  <oversight_info>
    <authority>Denmark: National Board of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The application of biomarkers that are more closely associated with eosinophillic airway
      inflammation, such as measurements of FeNO level, cell count in induced sputum or bronchial
      reactivity could improve asthma control by better directing treatment. A systematic review
      and meta-analysis is to be conducted to assess the efficacy of tailoring asthma intervention
      on clinical symptoms compared with exhaled nitric oxide or induced sputum count.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2012</start_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <target_duration>9 Months</target_duration>
  <primary_outcome>
    <measure>Control of asthma based on an algorithm</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>The use of NO and sputum cell count as a marker in asthma management</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>the use of ACQ and miniAQLQ</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Focus of Study is to Improve Asthma Control Based on Phenotype, NO and Sputum Cell Count</condition>
  <arm_group>
    <arm_group_label>Pulmicort</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pulmicort</intervention_name>
    <arm_group_label>Pulmicort</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Newly referred asthma patients
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  positiv mannitol

          -  asthma diagnose

        Exclusion Criteria:

          -  other lung disease
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Anne-Sophie Hom√∏e, student</last_name>
    <phone>+45 35313069</phone>
    <email>anne-sophie.homoee@regionh.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Respiratory research unit, Bispebjerg University Hospital</name>
      <address>
        <city>Copenhagen</city>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vibeke Backer, DmSci, md, prof.</last_name>
      <phone>+45 35313069</phone>
      <email>backer@dadlnet.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 6, 2013</lastchanged_date>
  <firstreceived_date>November 1, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bispebjerg Hospital</investigator_affiliation>
    <investigator_full_name>Vibeke Backer</investigator_full_name>
    <investigator_title>DmSci, professor, md</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Budesonide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
